Skip to main content

Table 2 Prognostic factors associated with recurrence-free survival

From: Antiviral therapy predicts the outcomes following resection of hepatocellular carcinoma in patients negative for HBV DNA: a propensity score matching analysis

 

Univariate analysis

Multivariate analysis

p value

HR

95% CI

p value

HR

95% CI

Gender

0.259

     

Age

0.895

     

AFP

0.381

     

BCLC

0.044

1.656

1.013–2.707

   

Tumor size

0.040

1.663

1.022–2.706

   

Tumor number

0.001

4.288

1.843–9.978

< 0.01

5.390

2.276–12.766

Capsule integrity

0.650

     

Satellite nodule

0.018

2.352

1.161–4.763

   

Vascular invasion

0.215

     

MVI

0.582

     

Necrosis

0.199

     

Liver cirrhosis

0.077

     

PHT

0.636

     

Anatomical hepatectomy

0.137

     

Blood loss

0.028

1.946

1.076–3.517

   

Operative time

0.509

     

ALT

0.042

1.655

1.017–2.693

   

ALB

0.726

     

TB

0.130

     

PT

0.757

     

Antiviral therapy

0.280

     

HBV reactivation

< 0.01

7.490

4.359–12.870

< 0.01

8.037

4.646–13.906

  1. AFP alpha-fetoprotein, BCLC Barcelona clinic liver cancer, MVI microvascular invasion, PHT portal hypertension, ALT alanine aminotransferase, ALB albumin, TB total bilirubin, PT prothrombin time, HBV hepatitis B virus
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us